Satya Ranjan Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Satya Ranjan Singh has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Shasanka Sekhar Swain
School of Biotechnology Centurion University of Technology and Management Bhubaneswar Odisha India
4 shared publications - Alaka Sahoo
Department of Skin & VD, Institute of Medical Sciences & SUM Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar 751003, Odisha, India
3 shared publications - Ayaluru Murali
Department of Bioinformatics, Pondicherry University
3 shared publications - Sanghamitra Pati
Indian Council of Medical Research
2 shared publications - Sudhir Kumar Paidesetty
Medicinal Chemistry Research Laboratory, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan Deemed to be University, Bhubaneswar 751003, Odisha, India
2 shared publications - Tahziba Hussain
ICMR-Regional Medical Research Centre, Bhubaneswar, India
2 shared publications
Latest Publications
- 16 June 2025
- Published by Wiley in Chemistry & Biodiversity
- p. e00662
Anti‐Inflammatory and Immunomodulatory Phytochemicals for Management of Oral Lichen Planus: A Multi‐Omics System Biology and Experimental Assessment
Oral lichen planus (OLP) is a chronic autoimmune inflammatory disorder where the exact pathophysiology remains unclear, posing challenges to effective treatment. The accumulative evidence suggested that anti‐inflammatory and immunomodulatory phytochemicals showed alternative therapeutic effects. Accordingly, the present study selected 28 multimodal phytochemicals (P1 to P28) and further assessed their potency and drug‐ability using computer‐aided drug design (CADD) and experimental methods. At first, the putative targets for OLP were selected through network pharmacology, and then molecular docking scores with predicted drug‐ability profiles recommended that P12 (epicatechin gallate/ECG) be the lead candidate among all. Furthermore, the protein–ligand stability of ECG against the nonsteroidal target cyclooxygenase‐2 (COX‐2) and the steroidal target glucocorticoid receptor (GR) was investigated using molecular dynamics (MD) simulations over 200 ns, and free energy calculations (MM/PBSA) were performed with GROMACS‐2020 software. The nontoxic dose for ECG was observed to be > 100 µM in three cell lines (HEK293, Huh7, and THP‐1). The gene expression results demonstrated that the COX‐2 and the proinflammatory cytokine IL‐1β significantly reduced, and the anti‐inflammatory cytokine IL‐10 slightly increased in a concentration‐dependent manner in inflammation‐induced (LPS‐treated) THP‐1 cells. Overall, the systematic computational and experimental results suggested that ECG could be a potent therapeutic option for managing OLP among the listed treatments.
- 16 June 2025
- Published by Wiley in Chemistry & Biodiversity
- p. e00662
Anti‐Inflammatory and Immunomodulatory Phytochemicals for Management of Oral Lichen Planus: A Multi‐Omics System Biology and Experimental Assessment
Oral lichen planus (OLP) is a chronic autoimmune inflammatory disorder where the exact pathophysiology remains unclear, posing challenges to effective treatment. The accumulative evidence suggested that anti‐inflammatory and immunomodulatory phytochemicals showed alternative therapeutic effects. Accordingly, the present study selected 28 multimodal phytochemicals (P1 to P28) and further assessed their potency and drug‐ability using computer‐aided drug design (CADD) and experimental methods. At first, the putative targets for OLP were selected through network pharmacology, and then molecular docking scores with predicted drug‐ability profiles recommended that P12 (epicatechin gallate/ECG) be the lead candidate among all. Furthermore, the protein–ligand stability of ECG against the nonsteroidal target cyclooxygenase‐2 (COX‐2) and the steroidal target glucocorticoid receptor (GR) was investigated using molecular dynamics (MD) simulations over 200 ns, and free energy calculations (MM/PBSA) were performed with GROMACS‐2020 software. The nontoxic dose for ECG was observed to be > 100 µM in three cell lines (HEK293, Huh7, and THP‐1). The gene expression results demonstrated that the COX‐2 and the proinflammatory cytokine IL‐1β significantly reduced, and the anti‐inflammatory cytokine IL‐10 slightly increased in a concentration‐dependent manner in inflammation‐induced (LPS‐treated) THP‐1 cells. Overall, the systematic computational and experimental results suggested that ECG could be a potent therapeutic option for managing OLP among the listed treatments.
- 14 March 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (14) , 7336-7347
Synthesis, spectroscopic analysis, and computational-based investigations on ‘azo-coumarin-Co(II)-galangin’ hybrids exhibit multipotential activities
The present study synthesized a series of cobalt (II) metal ion frame hybrid candidates (6a-6f) bearing phyto-flavonol galangin with substituted aryl diazenyl coumarins, and further structural confirmation was validated by various spectral techniques, including NMR, ATR-FTIR, UV-vis, HPLC, XRD, etc. Therapeutic potency was investigated via PASS (prediction of activity spectra for substances), molecular docking, molecular dynamics simulation, prediction of toxicity, pharmacokinetics, and drug-likeness scores, along with the highest occupied molecular orbital (HOMO), the lowest unoccupied molecular orbital (LUMO), with their energy gaps (ΔEH-L) to locate the most potential therapeutic candidates. The PASS prediction (Pa > Pi score) showed that proposed metal complexes have kinase inhibitors, antioxidative, and antischistosomal activities with potential molecular docking scores (> -7 kcal/mol) against selected targeted enzymes. Further, the MD-simulation (RMSD, RMSF, Rg, and H-bonds) of the most potential docking complex, 'HER2-6d', showed a minimum deviation similar to the standard drug (lapatinib) at 100 ns, indicating that 6d could be a potential noncovalent anticancer inhibitor. In addition, metal complexes possess a non-toxic and ideal drug-ability profiles, and positive electron space in an excited state increases the binding affinity towards target enzymes. Among all six ligands, 6c and 6d were the two most multipotent therapeutic agents from the above analyses. In summary, this could be a feasible approach towards the utilization of phytochemicals in mainstream therapeutic applications, where bioinformatics tools help to select a lead drug candidate at an early stage and guide for higher experimental success by proceeding with potential candidates.Communicated by Ramaswamy H. Sarma.
- 14 March 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (14) , 7336-7347
Synthesis, spectroscopic analysis, and computational-based investigations on ‘azo-coumarin-Co(II)-galangin’ hybrids exhibit multipotential activities
The present study synthesized a series of cobalt (II) metal ion frame hybrid candidates (6a-6f) bearing phyto-flavonol galangin with substituted aryl diazenyl coumarins, and further structural confirmation was validated by various spectral techniques, including NMR, ATR-FTIR, UV-vis, HPLC, XRD, etc. Therapeutic potency was investigated via PASS (prediction of activity spectra for substances), molecular docking, molecular dynamics simulation, prediction of toxicity, pharmacokinetics, and drug-likeness scores, along with the highest occupied molecular orbital (HOMO), the lowest unoccupied molecular orbital (LUMO), with their energy gaps (ΔEH-L) to locate the most potential therapeutic candidates. The PASS prediction (Pa > Pi score) showed that proposed metal complexes have kinase inhibitors, antioxidative, and antischistosomal activities with potential molecular docking scores (> -7 kcal/mol) against selected targeted enzymes. Further, the MD-simulation (RMSD, RMSF, Rg, and H-bonds) of the most potential docking complex, 'HER2-6d', showed a minimum deviation similar to the standard drug (lapatinib) at 100 ns, indicating that 6d could be a potential noncovalent anticancer inhibitor. In addition, metal complexes possess a non-toxic and ideal drug-ability profiles, and positive electron space in an excited state increases the binding affinity towards target enzymes. Among all six ligands, 6c and 6d were the two most multipotent therapeutic agents from the above analyses. In summary, this could be a feasible approach towards the utilization of phytochemicals in mainstream therapeutic applications, where bioinformatics tools help to select a lead drug candidate at an early stage and guide for higher experimental success by proceeding with potential candidates.Communicated by Ramaswamy H. Sarma.
- 29 January 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (21) , 11763-11780
pH modulates the role of SP6 RNA polymerase in transcription process: an in silico study
SP6 RNA polymerase (SP6 RNAP) is an essential enzyme for the transcription process in SP6 bacteriophage. SP6 RNAP plays a vital role in mRNA vaccine designing technology and other translational biotechnology research due to the high specificity towards its promoter. The self-replicating performance also put this polymerase to study extensively. Despite of the reports emphasizing the function of this enzyme, a detailed structural and functional understanding of RNA polymerase is not reported so far. Here, we report the first-ever information about SP6RNAP structure and its effect on promoter binding at different pH environments using molecular docking and molecular dynamics simulation (MDS) study. We also report the changes in polymerase conformations in different pH conditions using in-silico approach. The docking study was also performed for SP6 RNAP with SP6 promoter at different pH environments using the in-silico docking tools and conducted the MDS study for complexes. MM/PBSA and per residue energy contribution has been performed at three different pH environments. The structural aspects confirmed that the pH 7.9 state favors the polymerase functional activity in the transcription process which was in the range reported using transcription assay. This polymerase’s unique features may play its emerging role as an efficient transcription factor in translational biological research. Communicated by Ramaswamy H. Sarma The PRL and PBL of polymerase maintain a minimum distance from the promoter site at pH 7.9, leading to a possible transcription model for SP6 bacteriophage.
- 29 January 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (21) , 11763-11780
pH modulates the role of SP6 RNA polymerase in transcription process: an in silico study
SP6 RNA polymerase (SP6 RNAP) is an essential enzyme for the transcription process in SP6 bacteriophage. SP6 RNAP plays a vital role in mRNA vaccine designing technology and other translational biotechnology research due to the high specificity towards its promoter. The self-replicating performance also put this polymerase to study extensively. Despite of the reports emphasizing the function of this enzyme, a detailed structural and functional understanding of RNA polymerase is not reported so far. Here, we report the first-ever information about SP6RNAP structure and its effect on promoter binding at different pH environments using molecular docking and molecular dynamics simulation (MDS) study. We also report the changes in polymerase conformations in different pH conditions using in-silico approach. The docking study was also performed for SP6 RNAP with SP6 promoter at different pH environments using the in-silico docking tools and conducted the MDS study for complexes. MM/PBSA and per residue energy contribution has been performed at three different pH environments. The structural aspects confirmed that the pH 7.9 state favors the polymerase functional activity in the transcription process which was in the range reported using transcription assay. This polymerase’s unique features may play its emerging role as an efficient transcription factor in translational biological research. Communicated by Ramaswamy H. Sarma The PRL and PBL of polymerase maintain a minimum distance from the promoter site at pH 7.9, leading to a possible transcription model for SP6 bacteriophage.
- 16 May 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (11) , 4863-4872
Computational analysis of marine algal compounds for obesity management against pancreatic lipase
Obesity is considered a global crisis because of its increased risk factors triggered by lifestyle changes. The prevalence of this condition is increasing at an alarming rate, giving rise to development of novel drugs. Pancreatic lipase possesses higher efficacy in inhibiting this condition among the other drug targets. In this study, virtual screening of 126 plant-derived anti-obesity compounds and 1110 marine algal compounds from seaweed metabolite database were screened and targeted against pancreatic lipase and ranked based on their binding affinity values. A total of 530 compounds that possessed best docked scores of less than –6 kcal/mol were checked for Lipinski’s properties through Swiss ADME. Furthermore, these compounds were subjected to toxicity prediction using PROTOX II server. As much as 38 compounds were found to be non-toxic and were subjected to molecular docking analysis. Based on the binding energy, the following compounds RG012 (–10.15 kcal/mol), LIG42 (–9.7 kcal/mol), BC010 (–8.47 kcal/mol), RL073 (–8.2 kcal/mol), and LIG46 (–8.03 kcal/mol) were selected exhibiting higher binding affinity when compared to the standard drug (Orlistat) and hence these compounds were subjected to molecular dynamics simulation using GROMACS. BC010 complex revealed a stable interaction within the binding pocket and the binding free energy is –158.208 kJ/mol which is higher when compared to other complexes in 100 ns simulation. BC010 ((7S,11S,12S,14R)-4',14-dimethoxyamentol) from brown algae Cystophora fibrosa could be considered as a potential drug candidate to suppress obesity by inhibiting pancreatic lipase. Communicated by Ramaswamy H. Sarma
- 16 May 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (11) , 4863-4872
Computational analysis of marine algal compounds for obesity management against pancreatic lipase
Obesity is considered a global crisis because of its increased risk factors triggered by lifestyle changes. The prevalence of this condition is increasing at an alarming rate, giving rise to development of novel drugs. Pancreatic lipase possesses higher efficacy in inhibiting this condition among the other drug targets. In this study, virtual screening of 126 plant-derived anti-obesity compounds and 1110 marine algal compounds from seaweed metabolite database were screened and targeted against pancreatic lipase and ranked based on their binding affinity values. A total of 530 compounds that possessed best docked scores of less than –6 kcal/mol were checked for Lipinski’s properties through Swiss ADME. Furthermore, these compounds were subjected to toxicity prediction using PROTOX II server. As much as 38 compounds were found to be non-toxic and were subjected to molecular docking analysis. Based on the binding energy, the following compounds RG012 (–10.15 kcal/mol), LIG42 (–9.7 kcal/mol), BC010 (–8.47 kcal/mol), RL073 (–8.2 kcal/mol), and LIG46 (–8.03 kcal/mol) were selected exhibiting higher binding affinity when compared to the standard drug (Orlistat) and hence these compounds were subjected to molecular dynamics simulation using GROMACS. BC010 complex revealed a stable interaction within the binding pocket and the binding free energy is –158.208 kJ/mol which is higher when compared to other complexes in 100 ns simulation. BC010 ((7S,11S,12S,14R)-4',14-dimethoxyamentol) from brown algae Cystophora fibrosa could be considered as a potential drug candidate to suppress obesity by inhibiting pancreatic lipase. Communicated by Ramaswamy H. Sarma
- 13 April 2022
- Published by Wiley in Proteins: Structure, Function, and Bioinformatics
- Vol. 90 (9) , 1617-1633
Integrated bioinformatics–cheminformatics approach toward locating pseudo‐potential antiviral marine alkaloids against SARS‐CoV‐2‐Mpro
The emergence of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) with the most contagious variants, alpha (B.1.1.7), beta (B.1.351), delta (B.1.617.2), and Omicron (B.1.1.529) has continuously added a higher number of morbidity and mortality, globally. The present integrated bioinformatics–cheminformatics approach was employed to locate potent antiviral marine alkaloids that could be used against SARS‐CoV‐2. Initially, 57 antiviral marine alkaloids and two repurposing drugs were selected from an extensive literature review. Then, the putative target enzyme SARS‐CoV‐2 main protease (SARS‐CoV‐2‐Mpro) was retrieved from the protein data bank and carried out a virtual screening‐cum‐molecular docking study with all candidates using PyRx 0.8 and AutoDock 4.2 software. Further, the molecular dynamics (MD) simulation of the two most potential alkaloids and a drug docking complex at 100 ns (with two ligand topology files from PRODRG and ATB server, separately), the molecular mechanics/Poisson‐Boltzmann surface area (MM/PBSA) free energy, and contributions of entropy were investigated. Then, the physicochemical‐toxicity‐pharmacokinetics‐drug‐likeness profiles, the frontier molecular orbitals energies (highest occupied molecular orbital, lowest unoccupied molecular orbital, and ΔE), and structural–activity relationship were assessed and analyzed. Based on binding energy, 8‐hydroxymanzamine (−10.5 kcal/mol) and manzamine A (−10.1 kcal/mol) from all alkaloids with darunavir (−7.9 kcal/mol) and lopinavir (−7.4 kcal/mol) against SARS‐CoV‐2‐Mpro were recorded. The MD simulation (RMSD, RMSF, Rg, H‐bond, MM/PBSA binding energy) illustrated that the 8‐hydroxymanzamine exhibits a static thermodynamic feature than the other two complexes. The predicted physicochemical, toxicity, pharmacokinetics, and drug‐likeness profiles also revealed that the 8‐hydroxymanzamine could be used as a potential lead candidate individually and/or synergistically with darunavir or lopinavir to combat SARS‐CoV‐2 infection after some pharmacological validation.
- 13 April 2022
- Published by Wiley in Proteins: Structure, Function, and Bioinformatics
- Vol. 90 (9) , 1617-1633
Integrated bioinformatics–cheminformatics approach toward locating pseudo‐potential antiviral marine alkaloids against SARS‐CoV‐2‐Mpro
The emergence of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) with the most contagious variants, alpha (B.1.1.7), beta (B.1.351), delta (B.1.617.2), and Omicron (B.1.1.529) has continuously added a higher number of morbidity and mortality, globally. The present integrated bioinformatics–cheminformatics approach was employed to locate potent antiviral marine alkaloids that could be used against SARS‐CoV‐2. Initially, 57 antiviral marine alkaloids and two repurposing drugs were selected from an extensive literature review. Then, the putative target enzyme SARS‐CoV‐2 main protease (SARS‐CoV‐2‐Mpro) was retrieved from the protein data bank and carried out a virtual screening‐cum‐molecular docking study with all candidates using PyRx 0.8 and AutoDock 4.2 software. Further, the molecular dynamics (MD) simulation of the two most potential alkaloids and a drug docking complex at 100 ns (with two ligand topology files from PRODRG and ATB server, separately), the molecular mechanics/Poisson‐Boltzmann surface area (MM/PBSA) free energy, and contributions of entropy were investigated. Then, the physicochemical‐toxicity‐pharmacokinetics‐drug‐likeness profiles, the frontier molecular orbitals energies (highest occupied molecular orbital, lowest unoccupied molecular orbital, and ΔE), and structural–activity relationship were assessed and analyzed. Based on binding energy, 8‐hydroxymanzamine (−10.5 kcal/mol) and manzamine A (−10.1 kcal/mol) from all alkaloids with darunavir (−7.9 kcal/mol) and lopinavir (−7.4 kcal/mol) against SARS‐CoV‐2‐Mpro were recorded. The MD simulation (RMSD, RMSF, Rg, H‐bond, MM/PBSA binding energy) illustrated that the 8‐hydroxymanzamine exhibits a static thermodynamic feature than the other two complexes. The predicted physicochemical, toxicity, pharmacokinetics, and drug‐likeness profiles also revealed that the 8‐hydroxymanzamine could be used as a potential lead candidate individually and/or synergistically with darunavir or lopinavir to combat SARS‐CoV‐2 infection after some pharmacological validation.
- 15 February 2021
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 40 (14) , 6463-6476
Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment
At the health emergence, no such potent prophylactic therapy is available to control the deadly emerged Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). However, existing antiviral, anti-inflammatory, antimalarial drugs is the only option against SARS-CoV-2, but it may be harmful to patients without more clinical evidence. As an alternative solution, we proposed a newer hypothesis using the selective 10 potent anti-HIV drugs and flavonoid class of phytochemicals from previous reports to use in combination against SARS-CoV-2. Primarily, 10 anti-HIV protease inhibitor drugs and 10 phyto-flavonoids as ligands in molecular docking study against the putative target, the SARS-CoV-2-main protease (Mpro) ID: 6Y2E), as an essential enzyme in viral genome replication. According to molecular docking and drug-ability scores of each ligand, the anti-HIV drug, the darunavir (with a docking score, −10.25 kcal/mol and drug-likeness rating, 0.60) and the quercetin-3-rhamnoside (with a docking score, −10.90 kcal/mol and drug-likeness rating, 0.82) were selected for further analysis in combined effect. Perceptibly, the combined ‘anti-HIV drug and phyto-flavonoid’ docking complex has actively interacted with eight strong H-bonds with stability, briefly elucidated through RMRD-, RMSF- Rg-plots and MM/PBSA-binding energy calculation during 100 ns than the individual against SARS-CoV-2-Mpro. Thus, the ‘anti-HIV-drug-phyto-flavonoid’ combination therapy could be used against SARS-CoV-2 after some experimental validation. Communicated by Ramaswamy H. Sarma
- 15 February 2021
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 40 (14) , 6463-6476
Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment
At the health emergence, no such potent prophylactic therapy is available to control the deadly emerged Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). However, existing antiviral, anti-inflammatory, antimalarial drugs is the only option against SARS-CoV-2, but it may be harmful to patients without more clinical evidence. As an alternative solution, we proposed a newer hypothesis using the selective 10 potent anti-HIV drugs and flavonoid class of phytochemicals from previous reports to use in combination against SARS-CoV-2. Primarily, 10 anti-HIV protease inhibitor drugs and 10 phyto-flavonoids as ligands in molecular docking study against the putative target, the SARS-CoV-2-main protease (Mpro) ID: 6Y2E), as an essential enzyme in viral genome replication. According to molecular docking and drug-ability scores of each ligand, the anti-HIV drug, the darunavir (with a docking score, −10.25 kcal/mol and drug-likeness rating, 0.60) and the quercetin-3-rhamnoside (with a docking score, −10.90 kcal/mol and drug-likeness rating, 0.82) were selected for further analysis in combined effect. Perceptibly, the combined ‘anti-HIV drug and phyto-flavonoid’ docking complex has actively interacted with eight strong H-bonds with stability, briefly elucidated through RMRD-, RMSF- Rg-plots and MM/PBSA-binding energy calculation during 100 ns than the individual against SARS-CoV-2-Mpro. Thus, the ‘anti-HIV-drug-phyto-flavonoid’ combination therapy could be used against SARS-CoV-2 after some experimental validation. Communicated by Ramaswamy H. Sarma
- Open Access
- 1 November 2020
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 69 (11) , 1319-1331
Molecular evaluation of quorum quenching potential of vanillic acid against Yersinia enterocolitica through transcriptomic and in silico analysis
Introduction. Yersinia enterocolitica is one of the leading food-borne entero-pathogens causing various illnesses ranging from gastroenteritis to systemic infections. Quorum sensing (QS) is one of the prime mechanisms that control the virulence in Y. enterocolitica . Hypothesis/Gap Statement. Vanillic acid inhibits the quorum sensing and other virulence factors related to Y. enterocolitica . It has been evaluated by transcriptomic and Insilico analysis. Therefore, it can be a prospective agent to develop a therapeutic combination against Y. enterocolitica . Aim. The present study is focused on screening natural anti-quorum-sensing agents against Y. enterocolitica . The effect of selected active principle on various virulence factors was evaluated. Methodology. In total, 12 phytochemicals were screened by swarming assay. MATH assay, EPS and surfactant production assay, SEM analysis, antibiotic and blood sensitivity assay were performed to demonstrate the anti-virulence activity. Further, RNA sequencing and molecular docking studies were carried out to substantiate the anti-QS activity. Results. Vanillic acid (VA) has exhibited significant motility inhibition, thus indicating the anti-QS activity with MQIC of 400 µg ml−1 without altering the cell viability. It has also inhibited the violacein production in Chromobacterium violaceum ATCC 12472, which further confirms the anti-QS activity. VA has inhibited 16 % of cell-surface hydrophobicity (CSH), 52 % of EPS production and 60 % of surfactant production. Moreover, it has increased the sensitivity of Y. enterocolitica towards antibiotics. It has also made the cells upto 91 % more vulnerable towards human immune cells. The transcriptomic analysis by RNA sequencing revealed the down regulation of genes related to motility, virulence, chemotaxis, siderophores and drug resistance. VA treatment has also positively regulated the expression of several stress response genes. In furtherance, the anti-QS potential of VA has been validated with QS regulatory protein YenR by in silico molecular simulation and docking study. Conclusion. The present study is possibly the first attempt to demonstrate the anti-QS and anti-pathogenic potential of VA against Y. enterocolitica by transcriptomic and in silico analysis. It also deciphers that VA can be a promising lead to develop biopreservative and therapeutic regimens to treat Y. enterocolitica infections.
- 1 November 2020
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 69 (11) , 1319-1331
Open AccessMolecular evaluation of quorum quenching potential of vanillic acid against Yersinia enterocolitica through transcriptomic and in silico analysis
Introduction. Yersinia enterocolitica is one of the leading food-borne entero-pathogens causing various illnesses ranging from gastroenteritis to systemic infections. Quorum sensing (QS) is one of the prime mechanisms that control the virulence in Y. enterocolitica . Hypothesis/Gap Statement. Vanillic acid inhibits the quorum sensing and other virulence factors related to Y. enterocolitica . It has been evaluated by transcriptomic and Insilico analysis. Therefore, it can be a prospective agent to develop a therapeutic combination against Y. enterocolitica . Aim. The present study is focused on screening natural anti-quorum-sensing agents against Y. enterocolitica . The effect of selected active principle on various virulence factors was evaluated. Methodology. In total, 12 phytochemicals were screened by swarming assay. MATH assay, EPS and surfactant production assay, SEM analysis, antibiotic and blood sensitivity assay were performed to demonstrate the anti-virulence activity. Further, RNA sequencing and molecular docking studies were carried out to substantiate the anti-QS activity. Results. Vanillic acid (VA) has exhibited significant motility inhibition, thus indicating the anti-QS activity with MQIC of 400 µg ml−1 without altering the cell viability. It has also inhibited the violacein production in Chromobacterium violaceum ATCC 12472, which further confirms the anti-QS activity. VA has inhibited 16 % of cell-surface hydrophobicity (CSH), 52 % of EPS production and 60 % of surfactant production. Moreover, it has increased the sensitivity of Y. enterocolitica towards antibiotics. It has also made the cells upto 91 % more vulnerable towards human immune cells. The transcriptomic analysis by RNA sequencing revealed the down regulation of genes related to motility, virulence, chemotaxis, siderophores and drug resistance. VA treatment has also positively regulated the expression of several stress response genes. In furtherance, the anti-QS potential of VA has been validated with QS regulatory protein YenR by in silico molecular simulation and docking study. Conclusion. The present study is possibly the first attempt to demonstrate the anti-QS and anti-pathogenic potential of VA against Y. enterocolitica by transcriptomic and in silico analysis. It also deciphers that VA can be a promising lead to develop biopreservative and therapeutic regimens to treat Y. enterocolitica infections.